Top Tech Companies (2,059)
Don't see your company?
Create a company profile
At Intergalactic Therapeutics, we are building the future of non-viral gene therapy and expanding the therapeutic universe for patients.
MicroOptx is an early-stage medical device company that leverages academic bioengineering.
Precise liquid handling for biology
Heparinex is a biotechnology company.
LevitasBio is advancing science and human health by providing researchers with a new and powerful method of cellular processing and characterization. Our disruptive levitation technology overcomes current technological limitations by providing a gentle, simple and label-free method of isolating specific cell populations. The LeviCell platform enables studies and beneficial uses of previously inaccessible, high-value primary samples and sensitive cell types, regardless of the starting cell number, viability, or sensitivity to processing.
Aether’s mission is to build a future of abundance for the human race. We believe that the machinery of nature can be reverse engineered to manufacture any arrangement of atoms desired, enabling the production of new products anywhere on earth.
Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA. We are pioneering new territory, with an expedition led by a team of skilled scientists and drug development leaders who are inventive yet pragmatic. We are on a bold and exciting mission, a mission not without peril, but we have an energized, collaborative, creative and fearless team – a team that has consistently breached barriers and blazed new trails in search of solutions. We are now poised to realize the promise of bringing RNA into play for small-molecule drug discovery. Pushing the frontier of this emerging field of science is gratifying, but our mission goes beyond the thrill of scientific discovery. We believe that by targeting RNA biology in new ways, we have the potential to impact millions of patients. Our platform will allow us to reach hundreds of biological targets not currently accessible to medicine, including known targets previously considered “undruggable.” Our destination is powerful new therapies for patients everywhere, by opening up a new path for discovering RNA-targeted medicines.
Vascugen is a biotechnology company developing regenerative medicine for treatment of intractable vascular diseases.
Ascus Biosciences uses novel microbial community screening methods to discover, develop, and commercialize next generation feed additives.
Plexium is a drug development startup that leverages techniques from various physical-science and computational disciplines.
Dr. Raj Krishnan founded Biological Dynamics in 2010 with the goal to revolutionize diagnosis and treatment of high burden diseases. Under Raj's vision and guidance, Biological Dynamics has transformed from concept to early-stage startup and is now one of the most innovative diagnostic companies in Southern California. His passion and conviction have led Biological Dynamics through multiple rounds of funding, securing over $75 million in total. Raj has been recognized in the Top 30 under 30 scientists by Forbes magazine.
To use Susavion’s patented MultiValent Peptide Mimetic (MVPM) Technology platform to harness the innate power of the immune system to combat diseases with non-toxic, safe and effective treatments. At Susavion, we pride ourselves on doing things differently. We’re at the forefront of scientific innovation, leading the charge in the effort to solve some of healthcare’s most intractable problems. Our revolutionary therapy is safe and nontoxic, and we care about the people our research will benefit—always balancing our cutting-edge technology with our humanity.
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies. www.kiyatec.com
NewLeaf Symbiotics develops and commercializes the bacteria found in Pink Pigmented Facultative Methylotrophs.
Sevion is a biopharmaceutical company which discovers and develops entirely new therapeutic classes for the treatment of cancer.
Glooko is transforming digital health by connecting people with diabetes and related conditions and their healthcare teams, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms, Glooko® and diasend®, empower the management of diabetes and other chronic conditions by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected scales and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with over 95% of global diabetes devices along with health monitoring devices, giving people with diabetes and other chronic conditions and their care teams the freedom of choice. Over 3 million users have benefitted from health data insights using Glooko’s solutions, which are trusted by world leaders in diabetes and chronic care, and used in 29 countries across 22 languages.
A Mosaic company. Our diverse portfolio of products is backed by science and used worldwide to enhance yields, improve nutrient use efficiency, disease defense, biocontrol and abiotic stress. We’re committed to developing new soil health solutions that will provide advanced crop nutrition to customers around the globe and continue to help the world grow the food it needs.
Sempera Organics is a biotechnology company focused on wellness for humanity by unlocking the power of fungi. We provide mushroom products for many brands in a wide variety of industries.
A medical device company laying the foundation for vascular conduit replacement with its line of cell-free, synthetic scaffold products...
